StockNews.com Initiates Coverage on Cancer Genetics (NASDAQ:CGIX)

Analysts at StockNews.com assumed coverage on shares of Cancer Genetics (NASDAQ:CGIX – Get Rating) in a report issued on Sunday. The brokerage set a “sell” rating on the stock.

Cancer Genetics Trading Down 14.8 %

Shares of CGIX stock opened at $0.20 on Friday. The company has a market cap of $800,660.00, a price-to-earnings ratio of -0.09 and a beta of 2.72. The stock has a 50 day simple moving average of $0.38 and a 200-day simple moving average of $0.65. Cancer Genetics has a 12-month low of $2.11 and a 12-month high of $17.50.

Get Cancer Genetics alerts:

Cancer Genetics Company Profile

(Get Rating)

Vyant Bio, Inc is emerging as an advanced biotechnology drug discovery company. The firm is focused on human-powered scientific and technology-based systems to de-risk and accelerate the discovery and development of therapeutics for biopharma partners, as well as for its proprietary pipeline. The company with capabilities in data, science (both biology and chemistry), engineering, and regulatory, it rapidly identifying small and large molecule therapeutics and derisking decision making through multiple in silico, in vitro, and in vivo modalities.

See Also

• Get a free research report on Cancer Genetics from StockNews.com
• MarketBeat Week in Review – 6/19 – 6/23
• CarMax Stock Flying On Earnings Beat, Return Of The Highs?
• Commercial Metals Company Shakes Off The Rust: Confirms Uptrend
• Smith & Wesson, A Timeless Value Play At Decade Lows
• Five stocks we like better than Cancer Genetics

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.